CJC-1295 (no DAC)
Mod GRF 1-29 / Modified GRF
CJC-1295 (without DAC) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) consisting of amino acids 1-29 of GHRH with amino acid substitutions to increase stability and receptor binding affinity. Also known as Modified GRF(1-29) or Mod GRF, it produces pulsatile growth hormone release that more closely mimics natural physiology compared to the DAC variant. It is most commonly combined with a GHRP such as Ipamorelin to amplify GH output through dual-pathway stimulation.
Mechanism of Action
Modified growth hormone releasing hormone (GHRH) analog with amino acid substitutions at positions 2, 8, 15, and 27 to prevent enzymatic degradation. Stimulates pituitary GHRH receptors to amplify natural GH pulses without extending the pulse duration.
Research Protocols
For research purposes only. Not medical advice.
Research protocols use 100-200mcg 2-3 times daily via subcutaneous injection, typically combined with a GHRP (ipamorelin, GHRP-2, or GHRP-6). Administer on empty stomach 30 min before or 2 hours after meals.
Research Notes
Clinical Research Status
CJC-1295 without DAC has been studied in clinical trials demonstrating dose-dependent increases in GH and IGF-1 levels. The no-DAC version has a short half-life of approximately 30 minutes, requiring more frequent dosing but producing GH pulses rather than sustained elevation. No FDA approval exists for any indication; it remains an investigational compound available through research suppliers.
Key Published Findings
Clinical studies show that Modified GRF(1-29) increases GH secretion 2-10 fold when administered subcutaneously. Combination with GHRPs produces synergistic effects, with GH output greater than either compound alone. Research demonstrates improvements in body composition, sleep quality, and recovery markers in study participants over 4-12 week protocols.
Safety Profile
Side effects are generally mild and include transient flushing, headache, dizziness, and injection site reactions. Unlike exogenous GH, it preserves the hypothalamic-pituitary feedback loop, reducing risk of GH excess. Water retention and joint stiffness may occur at higher doses, consistent with elevated IGF-1 levels.
Drug Interactions & Contraindications
Should not be combined with somatostatin analogs (e.g., octreotide) which directly oppose its mechanism. Caution advised with glucocorticoids which suppress the GH axis. Contraindicated in individuals with active malignancy due to IGF-1's proliferative effects on certain cancer types.
Comparison to Related Compounds
The no-DAC version produces a short GH pulse (~30 min half-life) versus CJC-1295 with DAC which elevates GH for 6-8 days due to albumin binding. Most practitioners prefer no-DAC for its more physiological pulsatile pattern and lower risk of prolonged IGF-1 elevation. Sermorelin is an older, less potent GHRH analog that CJC-1295 has largely replaced in research settings.
Community Observations
Typically dosed at 100-300mcg subcutaneously 1-3 times daily, most commonly before bed and upon waking. The combination of Mod GRF + Ipamorelin at 100mcg each is considered the standard research protocol for GH optimization. Users report improved sleep quality, faster recovery, and gradual improvements in body composition over 3-6 month protocols.
Half-Life
~30 minutes
Reconstitution
Bacteriostatic water (BAC)
Storage
Lyophilized
Refrigerate 2-8C up to 18 months.
Reconstituted
Refrigerate 2-8C. Use within 14 days.
US Legal Status
Also Known As
PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.
Read full disclaimer